OPEX® Introduces the Next Generation in Goods-to-Person Warehouse Automation Technology - Infinity™ ASRS
28.3.2022 13:00:00 EEST | Business Wire | Press release
OPEX® Corporation, a global leader in warehouse automation technology, has added an innovative, industry-leading goods-to-person (G2P) solution to its Warehouse Automation portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005036/en/
The Infinity Goods-to-Person (G2P) solution (Photo: Business Wire)
The Infinity™ solution combines unparalleled storage density, configurability, and flexibility to meet the most pressing warehouse automation challenges for companies handling micro-fulfillment, omni-channel distribution, store replenishment, and ecommerce.
“Our focus is on engineering exciting new solutions that address unmet and evolving customer needs,” said Alex Stevens, President, OPEX Warehouse Automation. “The Infinity solution represents the next generation of goods-to-person technology to perfectly complement our existing Warehouse Automation product line.”
Automated G2P technology delivers the right item or SKU at the right time to the right operator or workstation, increasing productivity, throughput, and labor utilization by eliminating wasted time.
Powered by OPEX’s proprietary Cortex™ software platform, the Infinity G2P solution is engineered for maximum flexibility and scalability in both throughput and storage. Key benefits include reducing labor while increasing efficiency, storage density, and configurability.
Wireless Infinity iBOT® robotic vehicles access all inventory and port stations, moving freely underneath and throughout the system with no wasted mechanical motion, saving time and costs. Infinity iBOT robots are easily scalable by adding more iBOTs, presentation ports, and grids.
Unlike other competitive systems, the Infinity solution offers up to 35 percent more storage capacity with bot paths that are up to 65 percent more efficient.
The Infinity goods-to-person system utilizes a unique interlocking system to store totes triple-deep, eliminating wasted space and maximizing storage density. A configurable rack design optimizes warehouse space despite obstructions that may exist, such as columns or other equipment. The Infinity system’s flexibility also accommodates varied workflows and layouts.
The innovative Infinity solution was unveiled today at MODEX 2022, the industry’s premier material handling expo that showcases the latest in manufacturing and supply chain technology.
“Ecommerce is growing exponentially,” said Stevens. “Companies today need dependable yet advanced technology, the resiliency to meet shifting and seasonal demands, fast and accurate fulfillment, the ability to maximize space, and a partner they can trust. OPEX and the Infinity solution deliver all of this and more.”
Founded in 1973, OPEX brings generations of industry expertise and a proven track record developing first-class automation capabilities. The company is vertically integrated—innovating, engineering, manufacturing, selling, and servicing all of its automated solutions. This translates to the highest degree of quality equipment, reliable operations, product longevity, and an exceptional client experience.
The Infinity solution joins the existing Warehouse Automation portfolio at OPEX, which includes Sure Sort®—the industry-leading, high-speed, small-item robotic sorting system; and Perfect Pick®, a robotic goods-to-person picking solution that dramatically improves speed, efficiency, and reliability. All three solutions are custom configured for each client and designed to completely transform supply chain infrastructure.
To learn more, please visit warehouseautomation.com.
About OPEX
OPEX Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,500 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005036/en/
Contact information
Colleen Ciak
cciak@opex.com
+1 856.727.1100, ext. 5350
+1 856.912.4952 Cell
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom